IT’S TIME FOR SOMETHING NEW IN OVERACTIVE BLADDER TREATMENT

COMING SOON: NEW FDA-APPROVED
GEMTESA, A BETA-3 AGONIST FOR OVERACTIVE BLADDER1

Available April 2021

GEMTESA® is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.1

PROVEN EFFICACY

  • GEMTESA was effective in treating the symptoms of OAB in a 12-week clinical trial1
  • Symptoms treated include urge urinary incontinence, urgency, and urinary frequency1

ONCE-DAILY, 75-MG TABLET, NO TITRATION REQUIRED

  • GEMTESA tablets also may be crushed, mixed with a tablespoon (approximately 15 mL) of applesauce, and taken immediately with a glass of water1
  • If swallowed whole, take with a glass of water1

GEMTESA 75 MG WAS NOT ASSOCIATED WITH CLINICALLY SIGNIFICANT CHANGES IN BLOOD PRESSURE*

Reference: 1. GEMTESA [prescribing information] Irvine, CA. Urovant Sciences, GmbH.